This advanced master’s degree is an incredible opportunity to obtain in a single educational path, each and every one of the competences necessary to develop a totally updated intervention in Thoracic Oncology and Cardio-Oncologyy of total quality”

Today, to speak of oncology is to speak of multidisciplinary teams. Not losing this multidisciplinary vision is very important because many advances in one area can have implications in the diagnostic and therapeutic algorithms used in oncology. In fact, one of the skills that we aim for students to achieve with this advanced master’s degree is to have a broad and clear vision of oncology, and to use the comparison of scientific advances in each area as a tool that will allow them to advance their knowledge. 

We could give many examples, but for the sake of brevity we would just like to point out what immunotherapy has been and will be in the management of cancer. Apart from the results of interleukin-2 in melanoma and, to a lesser extent, in renal cancer, it was a therapy on its way to extinction, with little practical use in the management of patients. Since the approval of ipilimumab for the treatment of malignant melanoma, no more than 4 years ago, the development of immunotherapy in multiple tumors, and in particular in lung cancer, has increased and is already one of the most promising lines of research. 

This advanced master’s degree will allow the professional to acquire knowledge that will be extremely useful in daily work, based on critical work, a simple presentation and an effective methodology. We assume that simplicity is not incompatible with thoroughness, and through the acquisition of key knowledge, a critical spirit will emerge that will help to put this knowledge into practice. To this end, we offer you a cast of professors who are in the "first division" in the management of cancer, and many "international leaders", who have prepared in "depth each topic" from their vision as "super-specialists" but always bearing in mind that the ultimate goal of the advanced master’s degree is that the knowledge can be acquired by any physician interested in thoracic and cardiological cancers. 

Another aspect of the work of this specialization will focus on helping to increase personal potential, improve clinical decision making or the implementation of personalized oncology, thanks to collaboration and networking. 
The Professional Master's Degree will have two main axes around which all its modules will revolve: Research and clinical application. All sections will be approached from the perspective of the most recent research findings. From the research point of view, both basic and clinical research lines will be addressed. The research background of the directors and co-directors of the Master's Degree will be reflected in all the modules. As this is a master's degree with a clinical application vocation, all modules will be introduced, and their content will be applied to real clinical cases". 

An advanced master’s degree developed to provide a broad and up-to-date response to the needs of professionals in this area of intervention. The largest compendium of high quality scientific knowledge in the online teaching market”

This advanced master’s degree in Thoracic Oncology and Cardio-Oncology contains the most complete and up-to-date scientific program on the market. The most important features include:

• Clinical cases presented by experts in the different specialties
• Graphic, schematic, and practical contents with the latest scientific and healthcare information
• Diagnostic and Therapeutic Developments in Gynecology and Assisted Reproduction  
• Practical workshops on procedures, diagnosis and treatment techniques
• Real images in high resolution and practical exercises where the self-evaluation process can be carried out to improve learning
• Algorithm-based interactive learning system for decision-making in the presented clinical situations
• Special emphasis on test-based medicine and research methodologies
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

This Two Year TECH Master’s Degree is the best investment that you could make into your future. A specialization created to be compatible with your professional and personal life that will take you to your goal in the easiest way, optimizing your time and effort"

Its teaching staff is made up of leading professionals in the sector. Practicing professionals who bring their experience to this training program, as well as renowned specialists from leading scientific societies.  An impressive cast of super-specialists who will put their experience and professionalism at the service of this specialization. 

Thanks to its multimedia content developed with the latest educational technology, it will allow the professional a situated and contextual learning, that is to say, a simulated environment that will provide an immersive learning programmed to prepare in real situations.  

This program is designed around Problem-Based Learning, whereby the physician must try to solve the different professional practice situations that arise during the course. For this purpose, the physician will be assisted by an innovative interactive video system created by renowned and experienced experts in the field with extensive teaching experience.

This Two Year TECH Master’s Degree is the best investment that you could make into your future. A specialization created to be compatible with your professional and personal life that will take you to your goal in the easiest way, optimizing your time and effort"

Its contents, developed entirely by the best professionals in the sector, will allow you to assimilate the lessons learned through their experience, with the incomparable possibility of having real examples and therapeutic situations"

The main objective of this advanced master’s degree in Thoracic Oncology and Cardio-Oncology is to offer you a 360º quality specialization: the most complete syllabus, first class teachers from the best hospitals and scientific centers in the world, a highly efficient methodology and a learning system chosen for its excellent results. A combination that will lead you to achieve your goals in the easiest possible way, with total compatibility with your professional and personal life.  

This advanced master’s degree in Thoracic Oncology and Cardio-Oncology is oriented to the attainment of the most updated knowledge in Thoracic Oncology and Cardio-Oncology, in a single specialization and through a high impact educational path”

General Objectives

• Update Cardiologists’, Oncologists’, and Hematologists’ knowledge in the field of Cardio-Oncology 
• Promote work strategies based on a comprehensive approach to the patient as a standard model for achieving excellent care 
• Encourage the acquisition of technical skills and abilities, through a powerful audiovisual system, and the possibility of development through online simulation workshops and/or specific training
• Encourage professional stimulation through continuing education and research 
• To create a global and up-to-date vision of thoracic oncology and all its aspects, allowing the student to acquire useful knowledge and, at the same time, to generate interest in expanding the information and discovering its application in daily practice

Specific Objectives

Cardio-oncology Area

• Know the epidemiological relevance of cancer
• Know the clinical and epidemiological importance of cardiac toxicity
• Identify the epidemiological importance of prevention and early detection of cardiotoxicity 
• Learn the objectives of Cardio-Oncology Units
• Know the structure and organization of Cardio-Oncology Units
• Define the concept of cardiotoxicity 
• Learn the types of cardiotoxicity depending on the area affected 
• Learn the types of cardiotoxicity depending on the pathophysiological mechanism Understand the molecular and tissue mechanisms leading to CT 
• Recognize the cardiotoxic effects of thoracic radiotherapy 
• Update the knowledge of the evolution of radiothoracic radiotherapy equipment and methods 
• Explain the factors influencing acute and chronic radioinduced cardiotoxicity 
• Recognize chemotherapeutic drugs implicated in cardiotoxicity 
• Analyze the cardiotoxic effects of anthracyclines 
• Explain the cardiotoxic effects of anti-tubulin drugs
• Explain the cardiotoxic effects of antimetabolite drugs
• Explain the cardiotoxic effects of alkylating agents and other drugs that interact with DNA 
• Analyze the cardiotoxic effects of biological agents, specifically trastuzumabtype monoclonal antibodies
• Become familiar with other potentially cardiotoxic biological agents 
• Analyze the cardiotoxic effects of cell kinase inhibitors 
• Know other oncological treatments with potential cardiotoxic effect, such as anti-angiogenic drugs, histone deacetylase inhibitors, differentiation and/or apoptosis inducers and hormone therapy
• Understand the individual susceptibility factors, both genetic and acquired, involved in the development of cardiac toxicity
• Be able to perform a comprehensive risk assessment of patients undergoing oncologic treatment 
• Describe the monitoring required by patients during treatment for cardiotoxicity 
• Identify biomarkers as a method used to detect cardiotoxicity early, especially troponins and natriuretic peptides
• Delve into the knowledge of echocardiography, with special attention to the "global longitudinal strain" technique as a marker for early detection of cardiac toxicity
• Know the role of cardiac magnetic resonance imaging in the early detection of cardiotoxicity 
• Recognize the clinical relevance and mechanisms involved in the onset of ventricular dysfunction and heart failure secondary to cardiac toxicity 
• Deepen our knowledge of myocardial involvement caused by anthracyclines 
• Identify other chemotherapy drugs with the capacity to produce myocardial toxicity 
• Deepen our knowledge of myocardial toxicity induced by monoclonal antibodies, especially tratuzumab 
• Recognize the ability of therapies directed against new molecular targets (cellular kinase inhibitors) and proteosome inhibitors to produce ventricular dysfunction and heart failure
• Learn the effects of thoracic radiotherapy on the myocardium 
• Improve knowledge in the clinical diagnosis of heart failure associated with cardiotoxicity 
• Acquire updated knowledge in the treatment of heart failure and ventricular dysfunction related to oncological treatments 
• Know the importance of early detection of myocardial involvement due to cardiotoxicity 
• Describe the appropriate action to be taken in the event of an increase in circulating biomarkers during oncologic treatment 
• Describe the appropriate response to the appearance of "global longitudinal strain" alteration during oncological treatment
• Learn the monitoring strategy during treatment with anthracyclines 
• Learn the monitoring strategy during treatment with monoclonal antibodies, especially trastuzumab 
• Learn the monitoring strategy during treatment with cell kinase inhibitors 
• Understand the potential causes and mechanisms of ischemic heart disease in the context of cardiac toxicity 
• Identify patients at high risk of coronary artery disease 
• Define the role of oncological treatments such as fluoropyrimidines in the development of ischemic heart disease 
• Acquire updated knowledge on diagnostic methods for coronary artery disease related to cardiotoxic drugs 
• Get up to date on the management of acute coronary syndrome in the context of oncologic treatment 
• Learn the monitoring strategy in patients who have had coronary ischemia 
• Know the clinical relevance of thoracic radiotherapy in the development of coronary artery disease and its mechanisms 
• Recognize the risk factors for the development of ischemic heart disease in patients who have received thoracic radiotherapy 
• Expand knowledge of the diagnostic methods of radiation-induced coronary artery disease
• Analyze the treatment options in coronary artery disease associated with thoracic radiotherapy 
• Improve knowledge of the treatment strategy for chronic ischemic patients receiving oncologic treatment 
• Know the arrhythmogenic capacity and clinical relevance of cardiac toxicity 
• Learn the oncological treatments with the capacity to prolong the QT interval of the electrocardiogram and the factors that increase the probability of this occurring 
• Acquire in-depth knowledge of the electrocardiographic diagnosis of QT interval prolongation 
• Know the risk of developing ventricular arrhythmias and their specific treatment 
• Identify strategies to prevent prolongation of the QT interval on the electrocardiogram 
• Define the implications of prolongation of the QT interval on the electrocardiogram and the appearance of ventricular arrhythmias on the continuity of specific treatment 
• Recognize the clinical relevance and mechanisms of atrial tachyarrhythmias, especially atrial fibrillation in oncologic patients
• Learning about cancer treatments that favor the development of atrial fibrillation 
• Analyze the need for anticoagulation and its risk-benefit in oncologic patients with atrial fibrillation 
• Review the treatment options in atrial fibrillation in the context of cardiotoxicity 
• Recognize the clinical significance of bradyarrhythmias related to oncologic treatment 
• Learn the oncological treatments that are associated with the development of bradyarrhythmias and their therapeutic implications 
• Know the potential toxic effects of oncological treatments at the valvular level 
• Update knowledge on the attitude towards chronic valvular patients and prosthetic valve patient receiving oncological treatment
• Know the potential toxic effects of oncological treatments on the pericardium 
• Learn the treatment strategy for patients with pericardial effusion secondary to cardiac toxicity 
• Recognize the specific role of radiotherapy in the development of pericardial disease 
• Define the assessment of metastatic pericardial involvement 
• Recognize the clinical relevance of hypertension in oncologic patients 
• Analyze the relationship between antiangiogenic drugs and arterial hypertension and its mechanisms 
• Deepen the knowledge of the diagnosis of arterial hypertension associated with the use of antiangiogenic drugs 
• Define the strategy for monitoring arterial hypertension during oncologic treatment 
• Know the treatment of arterial hypertension related to oncologic treatment 
• Recognize the clinical relevance of venous thromboembolic disease in oncologic patients 
• Know the different factors and situations that contribute to the development of venous thromboembolic disease in oncologic patients 
• Learn the antineoplastic treatments associated with increased risk of venous thromboembolic disease 
• Describe prevention measures for cancer-related venous thromboembolic disease in different clinical scenarios 
• Analyze the relationship and clinical significance of venous thromboembolic disease with the use of central venous catheters 
• Learn the forms of clinical presentation, diagnostic and follow-up methods, as well as the treatment of venous thromboembolic disease with the use of central venous catheters
• Know the methods of prevention of venous thromboembolic disease with the use of central venous catheters
• Identify the forms of presentation and deepen the knowledge of the diagnosis of deep vein thrombosis and cancer-associated pulmonary thromboembolism
• Analyze the different therapeutic options for cancer-associated thromboembolic disease
• Know the capacity of some oncological treatments to produce arterial thrombosis 
• Recognize the clinical relevance and pathophysiological mechanisms of peripheral vascular disease in the oncologic patient 
• Know the treatments involved in the early development of peripheral vascular disease 
• Recognize the clinical significance and mechanisms involved in the occurrence of cerebral vascular disease in relation to oncological treatments 
• Know the oncological treatments associated with the appearance of cerebral vascular disease 
• Learn the relationship of some oncological treatments with the development of pulmonary hypertension 
• Define strategies to identify and control risk factors to limit the development of cardiotoxicity related to oncologic drugs 
• Know the measures capable of limiting cardiac toxicity due to anthracyclines 
• Know the measures capable of limiting cardiac toxicity due to trastuzumabtype monoclonal antibodies
• Know the measures capable of limiting cardiac toxicity related to cellular kinase inhibitors 
• Learn strategies to limit the risk of toxicity related to radiotherapy 
• Analyze the role of beta-blockers in cardioprotection 
• Analyze the role of angiotensin receptor inhibitors and antagonists in cardioprotection 
• Identify other pharmacological treatments with a possible cardioprotective effect 
• Become familiar with the follow-up required in patients with cardiac toxicity or at high risk of developing it
• Explain the long-term follow-up of patients who have received thoracic radiotherapy
• Understand the occurrence and determine the clinical management of patients with established oncologic disease who present with an acute ischemic event 
• Understand the occurrence and determine the clinical management of pediatric patients requiring potentially cardiotoxic oncologic treatment 
• Understand the onset and determine the clinical management of geriatric patients requiring oncologic treatment 
• Get up to date on anticoagulant and antiplatelet therapy in oncology patients 
• Broaden knowledge in relation to oncology patients with arrhythmias and require implantable devices (pacemakers, defibrillators) 
• Recognize the importance of research in the context of cardiotoxicity 
• Become familiar with current basic lines of research and future perspectives 
• Become familiar with current clinical lines of research and future perspectives

Thoracic Oncology Area

• Analyze the effectiveness of different tests proposed for lung cancer screening: low-resolution helical computed tomography, chest radiography and sputum cytology in the early diagnosis of lung cancer 
• Define the potential of other screening tests and estimate the population susceptible to be screened for lung cancer 
• Update knowledge in the molecular biology of cancer, especially in relation to the concept of genetic heterogeneity, circulating biomarkers and tissue molecular markers 
• Provide and expand knowledge on immunotherapy, as an example of a clear scientific advance in translational research, and one of the most promising lines of research in cancer treatment
• Create a global and updated vision of the exposed topics that allow the students to 
• Acquire useful knowledge and, at the same time, generate interest in expanding the information and discovering its application in their daily practice 
• Define the potential of other screening tests and estimate the population susceptible to be screened for lung cancer
• Review the performance and usefulness of each of the tests used in the diagnosis of thoracic tumors
• Describe the usefulness and performance of PET/CT with F18-FDG in the diagnosis, staging, treatment control and monitoring of thoracic tumors
• Learn more about thoracic MRI since it provides very complete anatomical information that can be fundamental for the patient's treatment, in addition to a functional assessment, and on many occasions its tissue characterization
• Review of available diagnostic tests for the assessment of cardiopulmonary reserve, necessary for the identification of patients at high risk of developing perioperative complications and significant long-term functional limitation after resection surgery
• Review the changes proposed for the new edition of the TNM, which imply a more accurate tumor staging
• Describe the evolution of current minimally invasive surgical techniques that allow complex surgeries to be performed with small incisions, preserving as much tissue as possible and with an accelerated recovery with less discomfort 
• Explain the basis of thoracic radiotherapy, as well as the different techniques available and their efficacy in order to understand their place in the management of thoracic tumors 
• Describe the new design of personalized clinical trials given the evidence that selective drugs have therapeutic benefits in molecularly defined subgroups of patients 
• Describe the therapeutic algorithm for the management of each of the thoracic tumors and in the different stages 
• Interpret the impact of mutations on drug selection 
• Discuss the current landscape of lung cancer immunotherapy, combinations in clinical development, strategies for dose selection and trial design, clinical pharmacology and regulatory considerations 
• Determine the positioning of each agent for the treatment of lung cancer 
• Construct an appropriate treatment plan for a patient with a thoracic tumor at each stage 
• Develop an appropriate treatment plan for patients with non-small cell lung cancer (NSCLC) that has progressed after initial treatment 
• Design a treatment plan for a patient with small cell lung cancer (SCLC) 
• Develop an appropriate treatment plan for a patient with SCLC that has progressed after initial treatment 
• Help improve the diagnosis and management of lower incidence tumors such as neuroendocrine tumors, mesothelioma, thymoma or tumors of the posterior mediastinum and thoracic wall 
• Update of knowledge on disseminated stage non-small cell lung cancer in different topics that, due to their topicality and importance, represent major changes for the clinical practice of any specialist in thoracic tumors 
• Discuss the growing understanding of the molecular biology and immunology of lung tumors and how they are modifying the diagnostic and therapeutic approach 
• Present the latest advances in translational research with practical implications 
• Assess the various therapeutic options available for first and subsequent lines of treatment in SCLC and neuroendocrine tumors 
• Explain the cell biology and genetics of low and intermediate grade neuroendocrine tumors 
• Identify the role of peptide receptor radionuclide therapy in the treatment of neuroendocrine lung tumors 
• Assess the efficacy and safety aspects of the different therapeutic options 
• Analyze the multidisciplinary treatment of pulmonary mesothelioma and future treatment options 
• Define the prognostic value of the anatomopathological classification of thymomas 
• Update on multidisciplinary thymoma treatment and future treatment options 
• Discuss the role of surgery in posterior mediastinal tumors 
• Delve into the diagnosis and treatment of thoracic wall tumors  
• Update on the treatment of secondary pulmonary metastases 
• Explain the different surgical options for the management of secondary lesions and their indications, which may, in turn, condition patient management 
• Explain the Enhanced support care strategy, developed by the Christie NHS Foundation Trust to better adapt patient care to the changing cancer landscape
• We must be aware that excellent care must be continuous and we must move towards integrated care models together with the rest of the specialists and, in particular, with primary care
• Improve the way of giving bad news to patients since, although there are as many ways of doing it as there are doctors and patients, there are some guidelines for the doctor to do it in the best way possible 
• Describe the vision of the emergency physician and how the detection of frequenters is a sign that can help improve the organizational model
• Learn the new therapeutic arsenal for the management of the main comorbidities of patients with thoracic tumors and know the therapeutic objectives in order to avoid poor control, therapeutic interactions or overtreatment 
• Assess the impact of age on patient prognosis and treatment outcomes 
• Explain the different online platforms available that can help us to follow up patients and create a professional network
• Learn the basics of decision support systems that facilitate decision making in complex contexts
• Describe the virtues of Big Data for the detection of relationships between variables that can help us in the knowledge and for multiple purposes

A practical specialization that will allow you to grow in your profession with the confidence of having all the essential support systems and flexibility to achieve with this program the skills of a top professional”